A bionic yeast for the colon-targeted delivery of curcumin in the treatment of inflammatory bowel disease

作者：Dunsheng Liang, Xiaofan Shen, Tingting Li, Yao Deng, Hong-Liang Xiao, Zhipeng Li, Shuan-Cheng Bai, Xiaoyu Ma, Xiaoping Liao, Donghao Zhao, Hao Ren, Chaoqun Zhang, Jian Sun, Lu Han · 发表于：Chemical Engineering Journal · 年份：2025 · DOI：10.1016/j.cej.2025.164121 · 被引用次数：10 · 研究领域：Polysaccharides and Plant Cell Walls、Microbial Metabolites in Food Biotechnology、Polysaccharides Composition and Applications

Inflammatory bowel disease (IBD) is a continuously increasing chronic inflammation, and it has been a worldwide health threat. Nevertheless, long-term treatments for IBD remain limited in clinical application. Curcumin is an ideal anti-oxidation and anti-inflammatory drug candidate for chronic inflammation and yet is still pharmacologically safe. However, its clinical application is limited by low solubility and poor bioavailability. To this end, we developed a colon-targeted curcumin carrier using β-glucan, sodium alginate (Alg) and chitosan (CS) named bionic yeast (BY) to improve the anti-inflammatory activity in IBD therapy. Saccharomyces cerevisiae -derived β-glucan greatly enhanced the bio-accessibility and colon-targeting release ability of curcumin. Moreover, the cell viability of bionic yeast demonstrated almost no toxicity on Caco-2 and RAW 264.7cells. The NO, iNOS, and proinflammatory factor including TNF-α, IL-1β, IL-6 were measured in LPS-induced RAW 264.7 cell line. These results indicated that bionic yeast containing β-glucan has a more pronounced anti-inflammatory effect than curcumin does. Therapeutic efficacy of bionic yeast was evaluated in DSS-induced IBD mouse model. It maintained the body weight, liver and spleen index triggered by DSS. The colon proinflammatory factor and inflammatory cell infiltration were significantly alleviated after receiving bionic yeast treatment. Furthermore, the bioavailability of bionic yeast was determined by pharmacokinetics....